Active Ingredient(s): Empagliflozin + Linagliptin
FDA Approved: * January 30, 2015
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Glyxambi Overview

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a drug combination used for the treatment of type 2 diabetes.[4][5] It is a combination of empagliflozin and linagliptin.[4][5] It was approved for use in the United States in January 2015,[6][7] and for use in the European Union in November 2016.[5] Contents 1 History 2 References 3 Further reading 4 External links...

Read more Glyxambi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Glyxambi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Empagliflozin + Linagliptin
  • Tablet: 10mg + 5mg, 25mg + 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Glyxambi: (3 results)

Sorted by National Drug Code
  • 0597-0164 Glyxambi Oral Tablet, Film Coated by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 0597-0182 Glyxambi Oral Tablet, Film Coated by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 70518-2046 Glyxambi Oral Tablet, Film Coated by Remedyrepack Inc.

Drugs with one or more similar ingredients: (12 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA